Alzheimer's specialists how it works ?

Alzheimer's disease treatments represent worldwide huge challengers and are among the most important nowadays concerns. The goal of the congress is to bring together today's worldwide leaders in the treatment of Alzheimer's disease in order to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer's disease treatments. It will also allow the participants to share their experience on the disease symptoms, and their skills on the dementia treatment. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments. Safe drugs represent some of the future treatment trials in order to avoid Alzheimer's disease progression. We learned at CTAD 2018 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Tau Biomarkers was proved to be one of the therapeutics combination as shown in the phase 43 clinical trials results. Studies on the early stage symptoms will be presented at the 2019 CTAD Congress by the clinical teams. The CTAD 2019 Congress will highlight the latest on trying to get these trials off the ground. Speeding the development of effective Alzheimer's treatment disease is one of the urge of the CTAD 2019 conference. The JPAD Journal of Prevention of Alzheimer's Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.